Cysts were removed with spinal fixation. All the patients showed relapses and needed at least three surgical interventions.

**Conclusion:** Bone echinococcosis is rare and often misdiagnosed. Radiographic and CT images lack disease-specific characteristics whereas MRI images offer a greater chance of direct diagnosis. Treatment of spinal hydatid disease is entirely surgical with high risk of relapses.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2021-eular.3896

---

**AB0785**

**TREATING IDIOPATHIC RECURRENT PERICARDITIS WITH INTERLEUKIN-1 INHIBITORS - A SINGLE CENTER EXPERIENCE**

P. Andrei1,2,3, S. Brådland2, G. Haugeberg2,4,1 Østfold Hospital Trust, Department of Cardiology, Sarpsborg, Norway; 2University of Oslo, Department of Clinical Medicine, Oslo, Norway; 3Hospital of Southern Norway, Department of Rheumatology, Kristiansand, Norway; 4Norwegian University of Science and Technology, Department of Neumedicine and Movement Science, Faculty of Medicine and Health Sciences, Rondheim, Norway

**Background:** Pericarditis is a common disease with significant morbidity (1). Idiopathic pericarditis, where an underlying cause cannot be identified, makes up for 80% of cases in the Western World (1). Up to 30% of these patients experience recurrence despite optimal treatment (2). Idiopathic recurrent pericarditis (IRP) is thought to represent an auto-inflammatory process rather than a reinfection (3). 2015 European Society of Cardiology (ESC) guidelines have outlined treatment of acute episodes and first recurrence with nonsteroidal anti-inflammatory drugs (NSAID), acetylsalicylic acid (ASS) and Colchicine as first line and Glucocorticoids (GC) as second line treatment (3). However GC treatment increases the risk of relapse, dependence and toxicity (2). Interleukin-1 (IL-1) inhibitors have been proposed as possible treatments in IRP (3, 4).

**Objectives:** The aim of this case study is to outline our first experiences treating IRP with the IL-1 inhibitor anakinra in our Rheumatologic clinic.

**Methods:** All patients referred to our department in 2018/2019 with pericarditis were physically seen in our outpatient clinic. All patients were screened for malignancy, infection or rheumatic disease as possible cause by clinical measures. Following ESC guideline, patients who suffered either the third recurrence under optimal treatment or significant side effects or dependency from GC were considered for anakinra treatment. Daily injection of anakinra (100mg) were given continuously over at least three months with gradual tapering over at least three months afterwards. Physical emergency department contacts, days hospitalized, colchicine- and GC use, the year prior to Anakinra treatment was recorded prospectively. During follow up the same data was prospectively recorded.

**Results:** Over the course of two years 20 patients were referred to our clinic. All fulfilled ESC diagnostic criteria for pericarditis at index episode. In none of the patients could a rheumatologic, infectious or malignant cause be identified. 16 patients could be treated according to 2015 ESC guidelines with first or second line agents. Four patients were aligned to anakinra-treatment. Prior to referral, patients could be treated according to 2015 ESC guidelines with first or second line agents.

**Conclusion:** Implementation of anakinra treatment in cases of complicated IRP was both secure and successful in our rheumatologic outpatient department. In our small sample we could confirm findings from bigger trials regarding effect and side effect rates of anakinra treating IRP.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2021-eular.4037

---

**AB0786**

**HUGHES–STOVIN SYNDROME: A PECULIAR AUTOIMMUNE ORIGIN OF PULMONARY ANEURYSMS**

P. Triggiani1, A. D’antonio1, B. Kroegler1, A. Ascoli Marchetti2, L. Beliviere2, D. Morosetti2, F. Sabuzzi2, A. Ioppi2, R. Agnani2, R. Perricone1,2

**Rheumatology, Allergology and Clinical Immunology, Department of “Medicina dei Sistemi”, University of Rome Tor Vergata, Rome, Italy; Vascular Surgery Unit, Biomedicine and Prevention Department, University of Rome Tor Vergata, Rome, Italy; 1Diagnostic Imaging and Interventional Radiology, University Hospital of Rome Tor Vergata, Rome, Italy

**Background:** Hughes-Stovin Syndrome (HSS) is a rare potentially fatal vasculitis supposedly belonging to the spectrum of Behçet disease without ocular involvement. HSS tends to play by a temporal pattern, starting with thrombosis and followed by formation of pulmonary aneurysms. Since its mortality can reach 25% of cases, the early recognition and the appropriate therapy represent the major challenges.

**Objectives:** In this report, we aimed at describing a rare case of HSS successfully treated in an early and extensive work-up for infections and autoimmunity did not document relevant abnormalities. An appropriate genetic assessment revealed the HLA-B51 positiv. The patient immediately underwent endovascular embolization with coils and plugs of the largest pulmonary aneurysm, and inferior vena cava filter placement. Then, he started methylprednisolone (1 mg/kg day) IV for three days in association with LMWH (6000 IU/day). Prednisone (1 mg/kg day) in combination with cyclophosphamide (100 mg daily) were started orally, with tapering of steroids within a month. At the tight follow up (1 month and 3 months later), no genial and oral ulcers nor vascular thrombosis occurred, and acute phase reactants were in normal range. The 3-month-CT angiography showed a complete resolution of the aneurysms and no new changes.

**Results:** The peculiar diagnosis of HLABS1 positive HSS with multiple pulmonary aneurysms was made. The appropriate imaging followed by a prompt endovascular embolization of aneurysms with LMWH treatment were successfully performed. Interestingly, the oral combination therapy with corticosteroid and cyclophosphamide showed a rapid efficacy with a relevant safety profile. At the tight follow up, the young man improved significantly with clinical signs and pulmonary changes (Figure 1 next page).

**Conclusion:** This case is of interest because of the early recognition of such a rare disease that allowed an adequate combined radiological, vascular, and rheumatologic approach. In our case, LMWH resulted useful in preventing the pulmonary embolism, despite the use of anticoagulants is still debated in HSS. Moreover, the endovascular embolization let a less invasive approach to surgery without the need for multiple surgical procedures. For the first time, we documented that oral cyclophosphamide showed an early efficacy as a first line therapy of a HLA-B51 HSS.

**REFERENCES:**